PROSEEK study shows no treatment benefit of Vodobatinib in patients with early Parkinson’s Disease
Both low dose and high dose Vodobatinib arms did not meet the pre-specified primary endpoint of change in MDS-UPDRS Part III total…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.